for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Valneva SE

VLS.PA

Latest Trade

13.81EUR

Change

-1.89(-12.04%)

Volume

4,933,410

Today's Range

12.68

 - 

14.00

52 Week Range

8.60

 - 

29.70

As of on the Euronext Paris ∙ Minimum 15 minute delay

Pricing

Previous Close
15.70
Open
13.10
Volume
4,933,410
3M AVG Volume
45.42
Today's High
14.00
Today's Low
12.68
52 Week High
29.70
52 Week Low
8.60
Shares Out (MIL)
99.76
Market Cap (MIL)
1,649.73
Forward P/E
-14.00
Dividend (Yield %)
--

Next Event

Full Year 2021 Valneva SE Earnings Release

Latest Developments

More

Vaccines company Valneva in talks with Scottish Enterprise for grant for Livingstone site

Valneva: Positive Homologous Booster Data For COVID-19 Vaccine Candidate

Valneva Signs Advance VLA2001 Purchase Agreement With Bahrain

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Valneva SE

Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.

Industry

Biotechnology & Drugs

Contact Info

6 rue Alain Bombard

44800

France

+33.2.28073710

https://valneva.com/

Executive Leadership

Frederic Grimaud

Chairman of the Supervisory Board

Thomas Lingelbach

Chairman of the Management Board, President, Chief Executive Officer, Member of the Management Board

Franck Grimaud

President, Chief Business Officer, Member of the Management Board

James R. Sulat

Independent Vice Chairman of Supervisory Board

Peter Buhler

Chief Financial Officer, Member of the Management Board

Key Stats

2.63 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2018

0.1K

2019

0.1K

2020

0.1K

2021(E)

0.1K
EPS (EUR)

2018

0.040

2019

-0.020

2020

-0.710

2021(E)

-1.188
Price To Earnings (TTM)
--
Price To Sales (TTM)
15.01
Price To Book (MRQ)
20.32
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
144.66
LT Debt To Equity (MRQ)
131.46
Return on Investment (TTM)
-43.70
Return on Equity (TTM)
-22.06

Latest News

Latest News

Vaccines company Valneva sticks to goal of COVID vaccine approvals in Q1

Speciality vaccines company Valneva said it was keeping its previous timetable on clinical trials and regulatory submissions for its VLA2001 COVID-19 vaccine candidate, with regulatory approvals targeted in the first quarter of this year.

Shares in COVID-19 vaccine developer Valneva extend fall

Shares in biotech company Valneva fell again on Wednesday, declining for the seventh day in a row due to a growing belief amongst investors that the COVID-19 Omicron variant might lessen the need for mass vaccination.

Valneva in talks with more countries interested in its COVID vaccine

French-Austrian biotech firm Valneva is in talks with a number of countries interested in its COVID-19 vaccine candidate and has the option to boost its production capacity in Scotland, its chief executive told Reuters.

Valneva says its booster works as a follow up to its own COVID-19 shot

French biotech firm Valneva said on Thursday its COVID-19 vaccine candidate was efficient as a booster for people who had received the same shot as an initial vaccination.

Valneva says no conclusions should be drawn on its vaccine from UK booster study

French biotech firm Valneva said on Friday no conclusions should be drawn on the effectiveness of its COVID-19 vaccine by a British study, which found it was the only shot out of seven that offered no immunity boost when given to people previously immunized with Pfizer's...

EU regulator begins real-time review of Valneva's COVID-19 shot

The European Union's drug regulator said on Thursday it had started a rolling review of the inactivated-virus COVID-19 vaccine from French biotech firm Valneva, weeks after the EU signed a deal with the company for supplies of the shot.

Valneva shares soar on EU deal for COVID-19 vaccine

French vaccines company Valneva's share price jumped more than 20% on Wednesday after it won European Commission approval for a deal under which it would supply up to 60 million doses of its COVID-19 vaccine candidate over two years.

UPDATE 2-Valneva shares soar on EU deal for COVID-19 vaccine

French vaccines company Valneva's share price jumped more than 20% on Wednesday after it won European Commission approval for a deal under which it would supply up to 60 million doses of its COVID-19 vaccine candidate over two years.

EU signs eighth COVID-19 vaccine deal with France's Valneva

The European Commission on Wednesday agreed to buy up to 60 million doses of French biotech company Valneva's potential COVID-19 vaccine, the eight such deal by the executive body as it speeds up its fight against rising infections.

BRIEF-European Commission Approves COVID-19 Vaccine Contract With Valneva

* EC: CORONAVIRUS: COMMISSION APPROVES CONTRACT WITH VALNEVA TO SECURE A NEW POTENTIAL VACCINE

Valneva says its COVID-19 vaccine shows similar protection to AstraZeneca's, fewer side effects

Valneva SE on Monday said its experimental COVID-19 vaccine demonstrated efficacy "at least as good, if not better" than AstraZeneca's shot in a late-stage trial comparing the two, with significantly fewer adverse side effects.

Valneva, Pfizer report good Phase 2 results for Lyme disease vaccine candidate

French vaccine company Valneva and U.S. drugmaker Pfizer announced on Tuesday more positive Phase 2 results, including on the booster response, for their Lyme disease vaccine candidate VLA15.

Valneva expands trials on COVID-19 vaccine candidate

French vaccine maker Valneva is expanding trials of a COVID-19 vaccine candidate called VLA2001, and remains in talks with the European Commission over a potential contract, the company said on Thursday.

UK would not have approved Valneva COVID vaccine, health secretary says

Britain cancelled its contract for about 100 million doses of a COVID-19 vaccine being developed by France's Valneva in part because it was clear it would not be approved for use in the country, UK Health Secretary Sajid Javid said on Tuesday.

Valneva stock slumps after Britain ends COVID vaccine deal

Valneva shares plunged 35% on Monday after the French drugmaker said the British government had ended a 1.4 billion euro ($1.65 billion) COVID-19 vaccine supply deal.

Exclusive: Some EU nations still want Valneva COVID-19 vaccine deal - sources

Some EU countries still want Brussels to strike a deal to buy Valneva's COVID-19 vaccine candidate despite a recent setback in talks, as the bloc aim to shore up and diversify supplies, sources familiar with the talks told Reuters.

EXCLUSIVE-Some EU nations still want Valneva COVID-19 vaccine deal - sources

Some EU countries still want Brussels to strike a deal to buy Valneva's COVID-19 vaccine candidate despite a recent setback in talks, as the bloc aim to shore up and diversify supplies, sources familiar with the talks told Reuters.

French vaccine maker Valneva and EU fail to strike supply deal

French vaccine maker Valneva has not met the conditions to conclude talks on a deal with the European Union to supply the bloc with its COVID-19 vaccine candidate, a spokesman for the European Commission said on Thursday.

EU says Valneva has not met conditions to reach agreement with EU on vaccine supply

Valneva has not met the conditions to conclude talks with the European Union on a supply deal of its COVID-19 vaccine candidate, a spokesman for the European Commission said on Thursday.

Valneva's COVID-19 shot set for Phase Three trial this month

Valneva on Tuesday reported positive results for its COVID-19 vaccine in early stage clinical trials and said it planned to launch a Phase Three trial this month.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up